Your browser doesn't support javascript.
loading
A modular and multi-functional purification strategy that enables a common framework for manufacturing scale integrated and continuous biomanufacturing.
Pybus, Leon P; Heise, Charles; Nagy, Tibor; Heeran, Carmen; Dover, Terri; Raven, John; Kori, Junichi; Burton, Graeme; Sakuyama, Hiroshi; Hastings, Benjamin; Lyons, Michelle; Nakai, Shinichi; Haigh, Jonathan.
Afiliação
  • Pybus LP; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Heise C; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Nagy T; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Heeran C; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Dover T; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Raven J; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Kori J; Bio Science & Engineering Laboratories, FUJIFILM Corporation, Kaisei, Japan.
  • Burton G; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Sakuyama H; Bio Science & Engineering Laboratories, FUJIFILM Corporation, Kaisei, Japan.
  • Hastings B; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Lyons M; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
  • Nakai S; Bio Science & Engineering Laboratories, FUJIFILM Corporation, Kaisei, Japan.
  • Haigh J; Process Development, FUJIFILM Diosynth Biotechnologies, Billingham, UK.
Biotechnol Prog ; 40(4): e3456, 2024.
Article em En | MEDLINE | ID: mdl-38494903
ABSTRACT
Biopharmaceutical manufacture is transitioning from batch to integrated and continuous biomanufacturing (ICB). The common framework for most ICB, potentially enables a global biomanufacturing ecosystem utilizing modular and multi-function manufacturing equipment. Integrating unit operation hardware and software from multiple suppliers, complex supply chains enabled by multiple customized single-use flow paths, and large volume buffer production/storage make this ICB vision difficult to achieve with commercially available manufacturing equipment. Thus, we developed SymphonX™, a downstream processing skid with advanced buffer management capabilities, a single disposable generic flow path design that provides plug-and-play flexibility across all downstream unit operations and a single interface to reduce operational risk. Designed for multi-product and multi-process cGMP facilities, SymphonX™ can perform stand-alone batch processing or ICB. This study utilized an Apollo™ X CHO-DG44 mAb-expressing cell line in a steady-state perfusion bioreactor, harvesting product continuously with a cell retention device and connected SymphonX™ purification skids. The downstream process used the same chemistry (resins, buffer composition, membrane composition) as our historical batch processing platform, with SymphonX™ in-line conditioning and buffer concentrates. We used surge vessels between unit operations, single-column chromatography (protein A, cation and anion exchange) and two-tank batch virus inactivation. After the first polishing step (cation exchange), we continuously pooled product for 6 days. These 6 day pools were processed in batch-mode from anion exchange to bulk drug substance. This manufacturing scale proof-of-concept ICB produced 0.54 kg/day of drug substance with consistent product quality attributes and demonstrated successful bioburden control for unit-operations undergoing continuous operation.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cricetulus / Reatores Biológicos Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Cricetulus / Reatores Biológicos Limite: Animals Idioma: En Ano de publicação: 2024 Tipo de documento: Article